All News

Abbott’s ID NOW COVID-19 test is able to deliver results in as little as 5 minutes.

Things to know about the root cause of chickenpox and shingles

Here’s a roundup of the latest coronavirus-related news from this week. 

Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.

Gilead has now asked the FDA to rescind its orphan drug status for the potential COVID-19 therapy.

Health care providers should look out for more than just respiratory diagnoses in patients when it comes to influenza-associated complications, according to a recent study. 

In a joint statement, the American Medical Association (AMA), American Pharmacists Association (APhA), and American Society of Health-System Pharmacists (ASHP) have communicated concerns regarding the inappropriate ordering, prescribing, or dispensing of treatments for COVID-19.

Tissue plasminogen activator, which is used to treat blood clots, may help severely ill patients with COVID-19 who are in respiratory failure, according to a new paper.

CVS Caremark’s new quantity limits will not affect members who are already receiving these medications for their approved uses.

A study investigated the use of lopinavir-ritonavir for the potential treatment of hospitalized patients with severe COVID-19.

The trials demonstrated a significant decrease in 24-hour coughs per hour versus placebo at 12 and 24 weeks.

Crisaborole ointment, 2% (Eucrisa, Pfizer) has been approved for use in pediatric patients with atopic dermatitis as young as 3 months of age.

After a steady climb, a new study showed that death rates for melanoma in the United States have dropped over the last few years.

The announcement follows their previous commitment to offering COVID-19 testing at local hospitals.

Pediatricians stress the importance of understanding the effects of COVID-19 on children.

Officials with the FDA have approved a 420-mg multi-dose of trastuzumab-bttb (Ontruzant, Samsung Bioepis), a biosimilar referencing trastuzumab (Herceptin).

Due to the increased need for albuterol inhalers in hospitals for COVID-19, shortages have been occurring in some areas of the country and will likely continue to affect supplies.

Increases in PrEP coverage were associated with reductions in HIV infections, a new study found.

Phase 3 clinical data demonstrate abrocitinib’s efficacy and safety in treating moderate-to-severe atopic dermatitis in adults.

The updated labeling recommends temporary discontinuation of SGLT2 inhibitors before scheduled surgery.

The FDA issued emergency use authorization of a rapid, point-of-care COVID-19 diagnostic test, developed by Cepheid, that has a detection time of approximately 45 minutes.

There is currently no scientific evidence suggesting that non-steroidal anti-inflammatory drug use could worsen COVID-19 in those infected.

A malaria drug that President Donald Trump said could possibly treat coronavirus disease (COVID-19) is already in short supply, according to ASHP. However, Teva said it will donate millions of tablets to US hospitals.

What new gaps will pharmacists need to fill?

The FDA previously approved sofosbuvir and velpatasvir to treat HCV in adults.

It’s my hope that 2020 is a profession changing year, starting with the schools of pharmacy.

Genentech is launching a phase 3 clinical trial evaluating tocilizumab (Actemra) plus standard of care for use in hospitalized adult patients with severe COVID-19 pneumonia.